Kornimate/medical-research-clean huggingface dataset:
incidence of hypotension in the post-anesthesia care unit (pacu).

Conditions: Hypotension During Surgery; Surgery-Complications

Summary: the perioperative period poses a heightened risk of complications for patients, including hypotension. while the issue of intraoperative hypotension is well-documented in medical literature, the occurrence and causes of hypotension in the post-anesthesia care unit often receive less attention. this phase of postoperative care, however, is vital for ensuring patient stability and preventing severe consequences. failure to identify and manage a drop in blood pressure can lead to hypoperfusion of critical organs, increasing the risk of morbidity and mortality. the aim of this study is to examine the frequency of hypotension in the post-anesthesia care unit-defined as systolic blood pressure \<90 mmhg or a drop of more than 20% from baseline-and to identify factors contributing to its development.

the perioperative period is a critical time for patients, marked by an increased risk of various complications, including hypotension. while intraoperative hypotension is extensively studied in medical literature, the occurrence and underlying causes of hypotension in the post-anesthesia care unit (pacu) often remain overlooked. this phase of postoperative care is essential for stabilizing the patient and preventing severe outcomes. a failure to identify and adequately address a drop in blood pressure during this time can result in hypoperfusion of vital organs, increasing the likelihood of morbidity and mortality. hypotension in the pacu is defined as a systolic blood pressure below 90 mmhg or a decrease exceeding 20% compared to the patient's baseline measurements. the aim of this research is to explore the prevalence of hypotension in the pacu and to analyze the factors contributing to its occurrence. by improving the understanding of this issue, the study seeks to enhance patient outcomes through timely identification and management of hypotension in this crucial phase of care.

Eligibility criteria:
inclusion criteria: * patients over 18 years old * patients undergoing a procedure under general anesthesia * patients who have consented to data processing * postoperative stay in pacu exclusion criteria: * patients younger than 18 years old. * patients transferred directly to the icu/anesthesiology and resuscitation department after surgery without staying in the recovery room. * patients with incomplete medical documentation or missing blood pressure values in the recovery room. * patients with a pre-existing diagnosis of resistant hypotension or unstable hemodynamics before surgery * patients with a history of long-term use of anxiolytics, antipsychotics, or other psychotropic medications that may affect cognitive function, emotional state, or predictive outcomes * patient refusal to participate in the study (including cases where they initially consented), with an emphasis on respecting patient autonomy

Keywords: hypotension post-anesthesia care unit surgery adult
evaluation of mineralized plasmatic matrix with and without collagen membrane in peri-implant bone regeneration

Conditions: Horizontal Alveolar Bone Defect; Alveolar Bone Loss

Summary: this study focuses on comparing the effect of mpm with or without collagen membrane on delayed implant placement in anterior maxillary aesthetic zone.


Eligibility criteria:
inclusion criteria: * patients with missing anterior maxillary teeth and having deficient alveolar thickness. * good oral hygiene * alveolar ridge width less than 4 mm. exclusion criteria: * medically compromised patients. * heavy smokers. * current chemotherapy or radiotherapy
effect alb-prf & a-prf in alveolar ridge preservation in diabetes patients - a rcct

Conditions: Tooth Extraction Status Nos

Summary: this study aim to investigate the effect of albumin gel- and platelet- rich fibrin(alb-prf) combined with advanced platelet-rich fibrin (a-prf) on alveolar ridge preservation by comparing alveolar ridge morphometric changes (hard and soft tissue), prospects and treatment complexity for placement of prosthetically guided dental implant, early oral wound healing outcomes evaluated by the inflammatory proliferative remodeling scale, and patient reported outcome measures, in type i/ii diabetes mellitus patient, versus spontaneous healing

diabetes is a well-established risk factor for oral diseases that often lead to extractions and tooth loss in the population, while diabetic patients also have increased susceptibility to wound infections. albumin gel-platelet-rich fibrin (alb-prf) and advanced platelet-rich fibrin (a-prf) are third-generation of platelet concentrates derived from a donor's blood by following a simple centrifugation protocol, heat treatment of platelet-poor plasma, and mixing of liquid-prf from the same preparation. this study proposes a novel alveolar ridge preservation technique based on the application of a-prf inside the extraction socket to sustain the release of growth factors during the early wound healing phase, together with periosteum inhibition by overlaying an alb-prf membrane with slow biodegradation and space maintenance properties over the bone to reduce post-extraction alveolar ridge resorption.

Eligibility criteria:
i. at least 18 years old with established tiidm diagnosis for more than 0.5 years, fasting blood glucose ≥7.0 mmol/l or 2 h plasma glucose ≥11.1 mmol/l, maximum hba1c levels under 8.0%. ii. non-smoker, diagnosed with generalized periodontitis stage iii or iv. iii. need for extraction of teeth, on opposing arches or opposing sides, with or without other concurrent indications for extractions: orthodontics, periodontitis, caries, fracture, root resorption, unrestorable root fragments. iv. at least one adjacent teeth/ implant is present at the site of extraction with a secure prognosis. v. no periapical lesions with a diameter of more than 5 mm (radiographically determined. vi. extraction socket with a bone height of at least 7mm at 2 walls. vii. reasonably aligned dental arches viii. will consider implant to replace missing teeth ix. willing and able to give informed consent. exclusion criteria: i. patients with conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability. ii. pregnancy or intention to become pregnant at any point during the study duration. iii. smoker /alcoholic iv. has platelet dysfunction/ thrombocytopenia/ blood dyscrasia v. on bisphosphonates or drugs that will significantly alter bone metabolism. vi. asa iii/iv.
a multiple ascending dose study of dt-216p2 in patients with friedreich's ataxia

Conditions: Friedreich Ataxia

Summary: the purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of dt-216p2 administered multiple ascending doses in patients with fa.


Eligibility criteria:
inclusion criteria: * participants must be 18-65 years of age inclusive, at the time of signing the informed consent. * genetically confirmed diagnosis of fa, with homozygous gaa repeat expansions in the frataxin gene. * stage 5.5 or less on the fsa at screening. * bmi between 16 and 32 kg/m2 at screening; weight should be \<= 100 kg at screening. * male and/or female using protocol defined and regulatory approved contraception. * capable of giving signed informed consent. exclusion criteria: * any concomitant medical condition that in the opinion of the investigator, puts the participant at risk or precludes participant from completing the study protocol. * any clinically significant nonmedical conditions and psychiatric disorders that could put the participant at higher risk for participation in the study, influence the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator. * received an investigational agent within the last 30 days or 5 half-lives, whichever longer, prior to the first dose of study drug, or are in follow-up of another clinical study prior to study enrollment. exception: potential participants who are currently on omaveloxolone must be on stable doses for at least 3 months. * is not willing to comply with the contraceptive requirements during the study period, as per protocol.
the value of 68ga-grazytracer pet in monitoring responses to immunotherapy of pancreatic cancer.

Conditions: Pancreatic Cancer

Summary: this study aims to investigate the value of 68ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.

the investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. all participants will undergo a 68ga-grazytracer pet/ct after 3 cycles of immunotherapy to evaluate response. the imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.

Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines 2. signed and dated informed consent form 3. commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .the patient is in good general condition with an expected survival of \&gt; 6 months exclusion criteria: 1. patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. intestinal perforation, complete intestinal obstruction 3. pregnant women and women who may be pregnant, women who are breastfeeding. 4. non-compliant person

Keywords: 68ga-grazytracer pet/ct pancreatic cancer immunotherapy
influence of pancreatic transection with cusa on postoperative pancreatic fistula incidence (pancut)

Conditions: Pancreatic Fistula

Summary: objective: to compare the outcomes after elective pancreatic resections using cavitron ultrasonic surgical aspirator (cusa) and selective closure of small blood vessels and branch pancreatic ducts versus surgical scalpel or stapler for the transection of pancreatic tissue. study design: a randomized controlled, single centre trial. study population: two groups of 80 patients (160 in total) scheduled for elective open pancreaticoduodenectomy (pd) for any indication. intervention: transection of pancreatic tissue with cusa. control: standard transection of pancreatic tissue with surgical scalpel (in pd) or stapler (in dp)

rationale: postoperative pancreatic fistula (popf) is one of the major causes of morbidity and mortality after pancreatic resections. there is no predominant surgical technique of pancreatic stump closure in distal pancreatectomy (dp) or formation of pancreaticojejunostomy in pancreaticoduodenectomy (pd) proven to prevent/lower popf incidence. cavitron ultrasonic surgical aspirator (cusa) selectively removes tissue parenchyma, evading blood vessels and pancreatic ducts which could consequently be selectively ligated. such technique could anull pancreatic juice drainage from branch ducts and provide better (skeletonised) view of the main duct to from an anastomosis (or to ligate it in dp) and thus lower the incidence of popf formation. objective: to compare transection of pancreatic tissue with cusa and selective closure of small blood vessels and branch pancreatic ducts with transection with surgical scalpel or stapler in elective pancreatic resections regarding the incidence of popf. study design: a randomized controlled, single centre trial. the study protocol was designed according to the spirit guidelines. study population: two groups of 80 patients (160 in total) scheduled for elective open pancreaticoduodenectomy (pd) for any indication. intervention: transection of pancreatic tissue with cusa. control: standard transection of pancreatic tissue with surgical scalpel (in pd). main study parameters/endpoints: primary outcome is the incidence of popf. main secondary outcomes are intraoperative outcomes (such as blood loss and operative time), postoperative outcomes (such as complications, time to functional recovery and hospital stay).

Eligibility criteria:
inclusion criteria: * patients aged 18 years or more * patients capable of understanding the provided information about the study * patients with signed informed consent * planned elective pancreaticoduodenectomy for any indication exclusion criteria: * patients aged less than 18 * patient incapable of understanding the provided information about the study * pregnancy * previous surgical procedures on pancreas * immunosuppressive therapy * preoperative radiotherapy

Keywords: pancreatic surgery pancreas transection postoperative complications popf
motivation in alcohol treatment facilities

Conditions: Alcohol Dependence; Alcohol Abuse

Summary: the purpose of this study is to determine if and to what extend a composite measure of treatment motivation and behavior change motivation predicts alcohol treatment success. it is expected that the composite measure based on the stages of the transtheoretical model of behavior change is a better predictor for treatment outcome than treatment motivation or behavior change motivation alone. participants will be recruited from alcohol treatment centers. a baseline interview regarding their motivation, drinking behavior and personal treatment goals will be conducted. at the end of treatment, treatment staff will be asked about treatment involvement of each participant. two follow-up interviews will be conducted after 6 and 12 months. to identify the impact of behavior change and treatment motivation on change in drinking behavior, data will be pooled with a non-treatment seeking sample. conclusions can be drawn on what motivation pattern best predicts behavior change for those utilizing formal help and for those remitting without formal help (self-changers).


Eligibility criteria:
inclusion criteria: * alcohol dependence * alcohol abuse exclusion criteria: * persons physically and mentally not capable of participating in study

Keywords: motivation to change treatment motivation alcohol use disorders
impact non hodgkins lymphoma (nhl) study

Conditions: Non-Hodgkin's Lymphoma

Summary: this is multi-center, international observational study of subjects receiving chop-14 or chop-21 (with or without rituximab) for the treatment of nhl. approximately 100-150 sites will contribute information on subjects treated at their institution.

this is a multi-center, international observational study of subjects receiving chop-14 or chop-21 (with or without rituximab) for the treatment of nhl. approximately 100-150 sites will contribute information on subjects treated at their institution. to avoid geographical bias, sites will be selected to represent the spread of subjects in each country. each site will be initially limited to 5 retrospective subjects and 10 prospective subjects (15 subjects per site) but sites may be asked to contribute further subjects to approximately 10 retrospective subjects and 20 prospective subjects. retrospective subjects may include any subject that has completed all cycles of chemotherapy treatment prior to date of site initiation. prospective subjects which may be considered for the study are any subject planned for chop-14 or chop-21 (with or without rituximab) treatment after the site initiation visit.

Eligibility criteria:
inclusion criteria: * subjects greater than or equal to 18 years old * subjects diagnosed with any histological type of nhl (including both chemotherapy naïve and pre-treated subjects) * subjects planned to receive a minimum of 3 cycles of chop-14 or chop-21 with or without rituximab (for subjects enrolled retrospectively, eligibility should be assessed on the profile at time of planning treatment, where treatment initiates on or after 01 jan 2005, with specific focus on planned chemotherapy and not outcome or number of delivered cycles) * before any study-specific procedure, the appropriate written informed consent must be obtained for countries where this is required exclusion criteria: * subjects receiving choep ((chop = cytoxan, hydroxyrubicin (adriamycin), oncovin (vincristine),etoposide, prednisone chemotherapy )or cnop (cytoxan, novantrone, oncovin (vincristine),etoposide, prednisone) chemotherapy are not eligible for inclusion in this study
comparison between individualized peep ventilation guided by driving pressure and conventional lung protective strategy in obese patients undergoing laparoscopic bariatric surgery

Conditions: Obese Patients With Bariatric Surgery; Lung Ultrasound Score

Summary: this study to compare the ventilation in obese patients either using driving pressure ventilation technique or conventional protective lung strategy all by using lung ultrasound score


Eligibility criteria:
inclusion criteria: 1. patients who have a bmi 30-40 kg/m2 2. american society of anesthesiologists (asa) physical status ii or iii 3. patients aged between 18 and 60 years, 4. patients scheduled to undergo laparoscopic bariatric surgeries. exclusion criteria: 1. patients' refusal to participate in the study, 2. previous history of thoracic surgery, 3. patients with a history of chest disease (copd, emphysema, or pneumothorax), 4. patients with abnormal pre-operative chest radiographs, such as pneumonia and pleural effusion, 5. patients with right-side heart failure or impending failure, 6. patients with known hypovolemia, and patients with increased intracranial pressure.
efficacy and safety of intravenous immunoglobulin ivig-f10 in patients with primary immunodeficiencies (pid)

Conditions: Agammaglobulinemia; IgG Deficiency; Common Variable Immunodeficiency

Summary: the purpose of this study is to demonstrate the effect of ivig-f10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. as secondary endpoints the rate of overall infections, the tolerability and safety of ivig-f10 are studied.


Eligibility criteria:
key inclusion criteria: * patients with primary immunodeficiency * regular ivig therapy for at least 6 months prior to receiving ivig-f10 key exclusion criteria: * allergic reactions to immunoglobulins or other blood products * steroids (oral and parenteral, daily ≥0.15 mg of prednisone equivalent/kg/day * history of cardiac insufficiency * epilepsia

Keywords: immunoglobulin intravenous agammaglobulinemia hypogammaglobulinemia common variable immunodeficiency immunoglobulin g children
female acl prevention study where we look at landing techniques pre/post nine week strenghtening program

Conditions: Prevention of ACL Thru Strengthening Program

Summary: to make reading this consent form easier, the word "participant" refers to you or your child (if a minor) throughout the consent form. this research is being done to study the effects of an eighteen-session strengthening program and to see if there is a relationship between the female athletes improving their landing techniques which has been proven to decrease anterior cruciate ligament injuries. participants have been asked to take part in a research study because you are a female athlete involved in a sport that has an increased anterior cruciate ligament injury rate. the purpose of this research study is to find out if an eighteen-session strengthening program will decrease your anterior cruciate ligament injury rate. there will be approximately ninety-four (94) people in this research study at henry ford health system (hfhs).

the purpose of this research program is to use dartfish technology and functional movement screen to assess female athletes pre- and post injury prevention program.the study will include ninety-four females: forty-seven who complete a nine week program focusing on neuromuscular and proprioceptive exercises to improve landing techniques, and forty-seven who go about their normal preseason training regimen. this program has no more risk than if each athlete were to work out at their own gym. each athlete will be given two questionnaires before and after completing the program in order to determine their level of activity has changed as well as uncover any underlying knee issues. participants will also go through a series of functional and movement tests to reveal any imbalances, and determine whether or not they have improved by going through the prevention program. all functional and movement tests will be video recorded. these recordings will only be used for the purpose of conducting this research study and will only be viewed by the hfhs investigators participating in the study. we will follow-up with each athlete one year later to see if there are any lasting effects from the program and re-test each athlete at that time to validate any results

Eligibility criteria:
inclusion criteria:females only age 13-16 - exclusion criteria:all males females younger than 13 and older than 16 -
prothrombin complex concentrate vs fresh frozen plasma in goal-directed bleeding management in liver transplantation surgery

Conditions: Liver Diseases

Summary: the primary endpoint of this study is the completion time of hemostasis treatment when administered fresh frozen plasma (ffp) and frozen powder coagulation factor concentrate (pcc) in goal-directed bleeding management for liver transplantation surgery.


Eligibility criteria:
inclusion criteria: * liver disease undergoing liver transplantation exclusion criteria: -
benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics

Conditions: Cancer; Pain

Summary: this study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. it is an efficacy study in adults and children and a randomized prospective study.


Eligibility criteria:
inclusion criteria: * patients suffering from cancer of any type, at any stage, hospitalized at the institut gustave roussy * aged from 6 to 14 years old (group a) and from 15 to 70 years old (adults) * presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis * pain resistant to morphinic treatment exclusion criteria: * cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (mi) of less than 3 months * neurological: non-controlled epilepsy, encephalopathy, or dementia * severe hepatic insufficiency * severe renal insufficiency * respiratory insufficiency * patients having surgery or in postoperative period * known deficit in g6pd, alanine exposure, or sulphamide treatment * porphyria * weight \> 80 kg

Keywords: cancer related visceral pain resistant to morphinics